Farxiga’s DAPA-HF trial at ESC - astrazeneca.com

1 Farxiga sDAPA-HF trial at ESCC onference call for investors and analysts1stSeptember 2019 Inorder,amongotherthings,toutilisethe'sa feharbour'provisionsoftheUSPrivateSecuri tiesLitigationReformAct1995,weareprovidi ngthefollowingcautionarystatement:thisdo cumentcontainscertainforward-lookingstat ementswithrespecttotheoperations,perform anceandfinancialconditionoftheGroup,incl uding,amongotherthings,statementsaboutex pectedrevenues,margins, ,anyforward-lookingstatements,bytheirver ynature, 'anticipates','believes','expects','inte nds' ,certainofwhicharebeyondourcontrol,inclu de,amongotherthings:thelossorexpirationo f,orlimitationsto,patents,marketingexclu sivityortrademarks,ortheriskoffailuretoo btainandenforcepatentprotection;effectso fpatentlitigationinrespectofIPrights;the impactofanydelaysinthemanufacturing,dist ributionandsaleofanyofourproducts;theimp actofanyfailurebythirdpartiestosupplymat erialsorservices;theriskoffailureofoutso urcing;therisksassociatedwithmanufacturi ngbiologics;theriskthatR&Dwillnotyieldne wproductsthatachievecommercialsuccess;th eriskofdelaytonewproductlaunches;therisk thatnewproductsdonotperformasweexpect;th eriskthatstrategicalliancesandacquisitio ns,includinglicensingandcollaborations,w illbeunsuccessful;therisksfrompressuresr esultingfromgenericcompetition.

2 Theimpactofcompetition,pricecontrolsandp ricereductions;therisksassociatedwithdev elopingourbusinessinemergingmarkets;ther iskofillegaltradeinourproducts;thediffic ultiesofobtainingandmaintainingregulator yapprovalsforproducts;theriskthatregulat oryapprovalprocessesforbiosimilarscouldh aveanadverseeffectonfuturecommercialpros pects;theriskoffailuretosuccessfullyimpl ementplannedcostreductionmeasuresthrough productivityinitiativesandrestructuringp rogrammes;theriskoffailureofcriticalproc essesaffectingbusinesscontinuity;economi c,regulatoryandpoliticalpressurestolimit orreducethecostofourproducts;failuretoac hievestrategicprioritiesortomeettargetso rexpectations;theriskofsubstantialadvers elitigation/governmentinvestigationclaim sandinsufficientinsurancecoverage;theris kofsubstantialproductliabilityclaims;the riskoffailuretoadheretoapplicablelaws,ru lesandregulations;theriskoffailuretoadhe retoapplicablelaws,rulesandregulationsre latingtoanti-competitivebehaviour;theimp actofincreasingimplementationandenforcem entofmorestringentanti-briberyandanti-co rruptionlegislation;taxationrisks;exchan geratefluctuations;theriskofanadverseimp actofasustainedeconomicdownturn;politica landsocio-economicconditions;theriskofen vironmentalliabilities;theriskofoccupati onalhealthandsafetyliabilities;theriskas sociatedwithpensionsliabilities.

3 Theimpactoffailingtoattractandretainkeyp ersonnelandtosuccessfullyengagewithourem ployees;theriskofmisuseofsocialmedialpla tformsandnewtechnology; statementsPresenters3 Pascal SoriotExecutive Director andChief Executive OfficerJohn McMurrayExecutive Director andChief Executive OfficerPresentersPascal SoriotExecutive Director andChief Executive OfficerProfessor John McMurrayMB ChB (Hons), MD, FRCP, FESC, FACC, FAHA, FRSE, FmedSci, OBEU niversity of Glasgow, UKAvailable for Q&ARuud DobberExecutive Vice President,BioPharmaceuticals Business UnitMene PangalosExecutive Vice President,BioPharmaceuticals R&DElisabeth Bj rkSenior Vice President,Late CVRMA genda for today s conference callIntroduction by Pascal SoriotClosing and Q&A4321 DAPA-HF presentation by Prof.

4 John McMurray5 astrazeneca @ ESC 2019 DAPA-HF another important milestone for FarxigaTHEMIS builds on positive BrilintamomentumFarxiga Positive DECLARE data in a broad patient population in type-2 diabetes Ground breaking results in heart failure (HFrEF) in both patients with and without type-2 diabetes DELIVER (HFpEF), data 2020+ US FDA Fast Track Designation in CKDB rilinta THEMIS shows statistically significant benefit for Brilintain patients with CAD and type-2 diabetes Positive risk/benefit in PCI subgroupHeart Failure:Prevent & treat 200mpeople with chronic kidney disease425m people affected with diabetesHigh unmet medical deaths per year64m people with HF Sources; 1. World Health Organization.

5 Cardiovascular diseases (CVDs). 2016. Accessed 30 August 2019. 2. International Diabetes Federation. About Diabetes. 2018. Accessed 30 August 2019. 3. OjoA. Addressing the global burden of chronic kidney disease through clinical and translational Am Clin ClimatolAssoc. 2014;125:229-43; discussion 243-6. 4. Vos T et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuriesfor 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study Lancet2017; 390(10100):1211-59. 5. Heidenreich , Forecasting the Impact of Heart Failure in the United States:A Policy Statement From theAmerican Heart Association.

6 CircHeart Fail. 2013 May; 6(3): 606 619.$31bnestimated costs in the US alone in 2012 CardiovascularDiabetesHeart FailureKidney Disease7 Innovative, complementary CVRM portfolioData 2020 Data 2020+** Enabling effective treatment for HF 8 Farxiga sDapa-HF trial at ESC 20199 Farxiga sDapa-HF trial at ESC 201910 Farxiga sDapa-HF trial at ESC 201911 Farxiga sDapa-HF trial at ESC 201912 Farxiga sDapa-HF trial at ESC 201913 Farxiga sDapa-HF trial at ESC 201914 Farxiga sDapa-HF trial at ESC 201915 Farxiga sDapa-HF trial at ESC 201916 Farxiga sDapa-HF trial at ESC 201917 Farxiga sDapa-HF trial at ESC 201918 Farxiga sDapa-HF trial at ESC 201919 Farxiga sDapa-HF trial at ESC 201920 Farxiga sDapa-HF trial at ESC 201921 Farxiga sDapa-HF trial at ESC 201922 Farxiga sDapa-HF trial at ESC 201923 Farxiga sDapa-HF trial at ESC 201924 Farxiga

7 SDapa-HF trial at ESC 201925 Farxiga sDapa-HF trial at ESC 201926 Farxiga sDapa-HF trial at ESC 201927 Farxiga sDapa-HF trial at ESC 201928 Farxiga sDapa-HF trial at ESC 201929 Farxiga sDapa-HF trial at ESC 201930 Farxiga sDapa-HF trial at ESC 201931 Farxiga sDapa-HF trial at ESC 2019Q&AUse of astrazeneca conference call, webcast and presentation slidesTheAstraZenecawebcast,conferenceca llandpresentationslides(togetherthe AstraZenecaMaterials )areforyourpersonal, ,reproduce,republish,post,broadcast,tran smit,makeavailabletothepublic, ,alter,adaptoraddtotheAstraZenecaMateria lsinanyway, ,advertising,endorsingorimplyinganyconne ctionbetweenyou(oranythirdparty)andus,ou ragentsoremployees, ,1 FrancisCrickAvenue,CambridgeBiomedicalCa mpus,Cambridge, +442037495000.